Orthofix Medical Inc. (NASDAQ:OFIX) Shares Purchased by Soleus Capital Management L.P.

Soleus Capital Management L.P. grew its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 686,374 shares of the medical device company's stock after purchasing an additional 79,441 shares during the quarter. Soleus Capital Management L.P. owned approximately 1.80% of Orthofix Medical worth $11,984,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Barclays PLC boosted its position in Orthofix Medical by 38.8% during the third quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock worth $1,912,000 after acquiring an additional 34,210 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Orthofix Medical by 480.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company's stock worth $1,318,000 after purchasing an additional 69,848 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Orthofix Medical by 24.3% during the 4th quarter. SG Americas Securities LLC now owns 21,279 shares of the medical device company's stock worth $372,000 after purchasing an additional 4,162 shares during the last quarter. Kirr Marbach & Co. LLC IN purchased a new stake in shares of Orthofix Medical in the fourth quarter valued at approximately $532,000. Finally, R Squared Ltd purchased a new stake in shares of Orthofix Medical in the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

Orthofix Medical Stock Down 0.5%

OFIX stock opened at $12.14 on Monday. Orthofix Medical Inc. has a one year low of $10.50 and a one year high of $20.73. The firm has a market cap of $473.73 million, a PE ratio of -3.88 and a beta of 0.87. The firm's 50 day moving average price is $14.39 and its 200-day moving average price is $16.78. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39.

Insiders Place Their Bets

In other Orthofix Medical news, CEO Massimo Calafiore acquired 10,000 shares of the business's stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average cost of $12.54 per share, with a total value of $125,400.00. Following the transaction, the chief executive officer now owns 234,603 shares of the company's stock, valued at $2,941,921.62. This trade represents a 4.45% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Lucas Vitale sold 4,287 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $16.60, for a total transaction of $71,164.20. Following the completion of the sale, the insider now owns 135,317 shares in the company, valued at approximately $2,246,262.20. This trade represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,475 shares of company stock valued at $128,065 over the last quarter. 1.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

OFIX has been the topic of a number of recent research reports. StockNews.com lowered Orthofix Medical from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group reissued a "buy" rating and set a $24.00 price target on shares of Orthofix Medical in a research report on Wednesday, February 26th. Finally, Roth Mkm reissued a "buy" rating and issued a $22.00 price objective on shares of Orthofix Medical in a report on Wednesday, February 26th.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.